Get started

Hillingdon Hospitals NHS Foundation Trust

Homepage: thh.nhs.uk
ROR: 04v0as660
OpenAlex ID: I2799786270
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 · Sunil Verma, David Miles, et al. · New England Journal of Medicine · 3,828
PDF
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
1955 · R H Thomlinson, L H Gray · British Journal of Cancer · 2,219
PDF
Reduction Potentials of One-Electron Couples Involving Free Radicals in Aqueous Solution
1989 · Peter Wardman · Journal of Physical and Chemical Reference Data · 2,117
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
2015 · Nicholas D James, Matthew R Sydes, et al. · The Lancet · 1,979
Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
2010 · Monique Maas, Patty J Nelemans, et al. · The Lancet Oncology · 1,945
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
2013 · Robert J. Motzer, Thomas E. Hutson, et al. · New England Journal of Medicine · 1,923
PDF
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 · Jonathan Ledermann, Philipp Harter, et al. · New England Journal of Medicine · 1,883
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial
2011 · Christopher M Nutting, James P Morden, et al. · The Lancet Oncology · 1,707
PDF
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
2012 · H.J. Schmoll, E. Van Cutsem, et al. · Annals of Oncology · 1,510
PDF
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
2013 · Joanne S Haviland, J Roger Owen, et al. · The Lancet Oncology · 1,470
PDF
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014 · Jonathan Ledermann, Philipp Harter, et al. · The Lancet Oncology · 1,442
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
2015 · Georgina V Long, Daniil Stroyakovskiy, et al. · The Lancet · 1,399
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
2019 · Caroline Robert, Jean J. Grob, et al. · New England Journal of Medicine · 1,386
PDF
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
2012 · Flaherty, K T, Robert, C, et al. · Zurich Open Repository and Archive (University of Zurich) · 1,330
PDF
Imaging biomarker roadmap for cancer studies
2016 · James P. B. O'Connor, Eric O. Aboagye, et al. · Nature Reviews Clinical Oncology · 1,088
PDF
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
2006 · Jean Bourhis, Jens Overgaard, et al. · The Lancet · 1,086
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
2020 · Adrian Murray Brunt, Joanne S Haviland, et al. · The Lancet · 1,084
PDF
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 · P. H. Maxwell, G. U. Dachs, et al. · Proceedings of the National Academy of Sciences · 1,082
Antioxidant activities of carotenes and xanthophylls
1996 · Nicholas J. Miller, Julia Sampson, et al. · FEBS Letters · 1,026
Mapping the human genetic architecture of COVID-19
2021 · COVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, et al. · Nature · 983
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
2020 · Sandra M Swain, David Miles, et al. · The Lancet Oncology · 914
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
2007 · David P Dearnaley, Matthew R Sydes, et al. · The Lancet Oncology · 905
Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?
2012 · Fergus Davnall, Connie S. P. Yip, et al. · Insights into Imaging · 877
PDF
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
2015 · Amit M Oza, Adrian D Cook, et al. · The Lancet Oncology · 875
PDF
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
1997 · Martin R Cowie, Allan D Struthers, et al. · The Lancet · 872
Works count: 873
Citation count: 27,040
Year
Topic
Type